利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

116 条记录 (耗时 0.017 秒)

    INFRARED THERMOGRAPHY AND METHODS OF USE
    81.
    发明公开
    INFRARED THERMOGRAPHY AND METHODS OF USE 有权
    红外热像仪和性功能障碍治疗

    公开(公告)号：EP1284653A2

    公开(公告)日：2003-02-26

    申请号：EP01935124.6

    申请日：2001-05-08

    申请人： Nitromed, Inc.

    发明人： MAREK, Przemyslaw, A. ,  TROCHA, Andrzej, M.

    IPC分类号： A61B6/00

    CPC分类号： A61B5/4368 ,  A61B5/015 ,  A61K49/0004 ,  Y10S514/929

    摘要： The present invention describes rapid non-invasive methods for measuring vasodilation or changes in blood flow in a patient following administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The method comprises administration of at least one compound to the patient followed by monitoring the temperature change of an area of interest using infrared thermography.

    ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION
    82.
    发明公开
    ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION 审中-公开
    低氧内源性一氧化氮条件下

    公开(公告)号：EP1242068A1

    公开(公告)日：2002-09-25

    申请号：EP00975366.6

    申请日：2000-10-26

    申请人： Nitromed, Inc.

    发明人： Saenz DE Tejada, Inigo

    IPC分类号： A61K31/195

    CPC分类号： A61K45/06 ,  A61K31/155 ,  A61K31/195 ,  A61K31/198 ,  A61K2300/00

    摘要： The present invention provides methods of promoting synthesis of nitric oxide or endothelium-derived relaxing factor (EDRF) in hypoxic mammalian tissues by administering at least one N-hydroxyguanidine compound that is a substrate of nitric oxide synthase and at least one thromboxane inhibitor, and, optionally, one or more vasoactive agents. The present invention also provides methods of promoting vasorelaxation and treating sexual dysfunctions in patients by administering at least one N-hydroxyguanidine compounds that is a substrate for nitric oxide synthase and at least one thromboxane inhibitor, and, optionally, one or more vasoactive agents. The present invention also provides methods for treating clinical conditions resulting from hypoxic conditions such as pulmonary disease, cardiovascular disorders, circulatory hypoxia, specific organ hypoxia, localized hypoxia, edema, central nervous system disorders, memory loss, or arterial disease. The present invention also provides methods for treating clinical conditions resulting from a high level of arginase activity, such as, heart disease, systemic hypertension, pulmonary hypertension, sexual dysfunction, autoimmune disease, chronic renal failure and cerebral vasospasm. The present invention also provides methods for treating clinical conditions associated with a deficient nitric oxide pathway by the administration of at least one N-hydroxyguanidine compound and at least one thromboxane inhibitor, and, optionally, one or more vasoactive agents. The present invention also provides pharmaceutical compositions comprising at least one N-hydroxyguanidine compound and at least one thromboxane inhibitor, and, optionally, one or more vasoactive agents.

    ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION
    86.
    发明公开
    ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION 有权
    刺激内源性NO的合成低氧条件下

    公开(公告)号：EP1082112A1

    公开(公告)日：2001-03-14

    申请号：EP99925993.0

    申请日：1999-06-01

    申请人： Nitromed, Inc.

    发明人： SAENZ DE TEJADA, Inigo

    IPC分类号： A61K31/195

    CPC分类号： A61K45/06 ,  A61K31/155 ,  A61K31/198

    摘要： The present invention provides methods of promoting synthesis of nitric oxide or endothelium-derived relaxing factor (EDRF) in hypoxic mammalian tissues by administering at least one N-hydroxyguanidine compound that is a substrate of nitric oxide synthase, and, optionally, one or more vasoactive agents. The present invention also provides methods of promoting relaxation of vascular and non-vascular smooth muscle and treating sexual dysfunctions in patients by administering at least one N-hydroxyguanidine compound that is a substrate for nitric oxide synthase, and, optionally, one or more vasoactive agents. The present invention also provides methods for treating clinical conditions resulting from hypoxic conditions, such as pulmonary disease, cardiovascular disorders, circulatory hypoxia, specific organ hypoxia, localized hypoxia, edema, central nervous system disorders, memory loss, or arterial disease. The present invention also provides methods for treating clinical conditions associated with deficient nitric oxide pathways by administering at least one N-hydroxyguanidine compound and, optionally, one or more vasoactive agents. The present invention also provides pharmaceutical compositions comprising at least one N-hydroxyguanidine compound and, optionally, one or more vasoactive agents.